Optineurin in patients with Amyotrophic Lateral Sclerosis associated to atypical Parkinsonism in Tunisian population

References

• Mead RJ, Shan N, Reiser HJ, Marshall F, Shaw PJ. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discov. 2023;22:185–212.
   PubMed Web of Science ®Google Scholar
• Shi G, Zhou J, Huang K, Bi FF. Trends in global amyotrophic lateral sclerosis research from 2000 to 2022: a bibliometric analysis. Front Neurosci. 2022;16:965230. Available at: https://www.frontiersin.org/articles/10<?sch-permit JATS-0034-007?>.3389/fnins.2022.965230. Accessed November 3, 2022.
   PubMed Web of Science ®Google Scholar
• Keon M, Musrie B, Dinger M, Brennan SE, Santos J, Saksena NK. Destination Amyotrophic Lateral Sclerosis. Front Neurol. 2021;12:596006. Available at: https://www.frontiersin.org/articles/10<?sch-permit JATS-0034-007?>.3389/fneur.2021.596006. Accessed November 3, 2022.
   PubMed Web of Science ®Google Scholar
• Blokhuis AM, Groen EJN, Koppers M, van den Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125:777–94.
   PubMed Web of Science ®Google Scholar
• McCann EP, Henden L, Fifita JA, Zhang KY, Grima N, Bauer DC, et al. Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis. J Med Genet 2020:1–9.
   Web of Science ®Google Scholar
• Sghaier I, Kacem I, Ticozzi N, Mrabet S, Paverelli S, Abida Y, et al. The oligogenic model of amyotrophic lateral sclerosis; phenotypes of three Tunisian families. Clin Genet. 2022; Dec102:555–6.
   PubMed Web of Science ®Google Scholar
• Suzuki N, Nishiyama A, Warita H, Aoki M. Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy. J Hum Genet. 2023;68:131–52.
   PubMed Web of Science ®Google Scholar
• Liu G, Byrd A, Warner AN, Pei F, Basha E, Buchanan A, et al. Cdc48/VCP and endocytosis regulate TDP-43 and FUS toxicity and turnover. Mol Cell Biol. 2020;40:e00256-19.
   PubMed Web of Science ®Google Scholar
• Prtenjaca N, Rob M, Alam MS, Markovinovic A, Stuani C, Buratti E, et al. Optineurin deficiency and insufficiency lead to higher microglial TDP-43 protein levels. Int J Mol Sci 2022;23:6829.
   PubMed Web of Science ®Google Scholar
• Yamashita S, Kimura E, Tawara N, Sakaguchi H, Nakama T, Maeda Y, et al. Optineurin is potentially associated with TDP-43 and involved in the pathogenesis of inclusion body myositis. Neuropathol Appl Neurobiol. 2013;39:406–16.
   PubMed Web of Science ®Google Scholar
• Medchalmi S, Tare P, Sayyad Z, Swarup G. A glaucoma- and ALS-associated mutant of OPTN induces neuronal cell death dependent on Tbk1 activity, autophagy and ER stress. FEBS J. 2021;288:4576–95.
   PubMed Web of Science ®Google Scholar
• Wong YC, Holzbaur ELF. Optineurin is an autophagy receptor for damaged mitochondria in parkin-mediated mitophagy that is disrupted by an ALS-linked mutation. Proc Natl Acad Sci U S A. 2014;111:E4439–48.
   PubMed Web of Science ®Google Scholar
• Toth RP, Atkin JD. Dysfunction of optineurin in amyotrophic lateral sclerosis and glaucoma. Front Immunol. 2018;9:1017.
   PubMed Web of Science ®Google Scholar
• Luna J, Diagana M, Ait Aissa L, Tazir M, Ali Pacha L, Kacem I, et al. Clinical features and prognosis of amyotrophic lateral sclerosis in Africa: the TROPALS study. J Neurol Neurosurg Psychiatry. 2019;90:20–9.
   PubMed Web of Science ®Google Scholar
• Marin B, Kacem I, Diagana M, Boulesteix M, Gouider R, Preux PM, et al. Juvenile and adult-onset ALS/MND among Africans: incidence, phenotype, survival: a review. Amyotroph Lateral Scler. 2012;13:276–83.
   PubMed Web of Science ®Google Scholar
• Kacem I, Sghaier I, Peverelli S, Souissi E, Ticozzi N, Gharbi A, et al. Genotype-phenotype correlation in Tunisian patients with Amyotrophic Lateral Sclerosis. Neurobiol Aging. 2022;120:27–33.
   PubMed Web of Science ®Google Scholar
• Kacem I, Sghaier I, Ticozzi N, Mrabet S, Paverelli S, Nasri A, et al. Expanding the phenotype of TARDBP mutation in a Tunisian family with clinical phenotype heterogeneity. Amyotroph Lateral Scler Front Degener. 2022;0:1–4.
   Google Scholar
• Ben Halim N, Ben Alaya Bouafif N, Romdhane L, Kefi Ben Atig R, Chouchane I, Bouyacoub Y, et al. Consanguinity, endogamy, and genetic disorders in Tunisia. J Community Genet. 2013; Apr4:273–84.
   PubMedGoogle Scholar
• Byrne S, Bede P, Elamin M, Kenna K, Lynch C, McLaughlin R, et al. Proposed criteria for familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12:157–9.
   PubMed Web of Science ®Google Scholar
• Ben Jemaa S, Attia Romdhane N, Bahri-Mrabet A, Jendli A, Le Gall D, Bellaj T. An Arabic version of the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-Cog): reliability, validity, and normative data. J Alzheimers Dis. 2017;60:11–21.
   PubMed Web of Science ®Google Scholar
• Kacem I, Abida Y, Ferchichi W, Gharbi A, Sghaier I, Souissi A, et al. Arabic adaptation of the Edinburgh Cognitive and behavioural Amyotrophic Lateral Sclerosis Screen (ECAS). Rev Neurol (Paris). 2022;178:817–25.
   PubMed Web of Science ®Google Scholar
• Capriotti E, Fariselli P, Casadio R. I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res. 2005;33:(Web Server issue):W306–310.
   PubMed Web of Science ®Google Scholar
• Cheng J, Randall A, Baldi P. Prediction of protein stability changes for single-site mutations using support vector machines. Proteins 2006;62:1125–32.
   PubMed Web of Science ®Google Scholar
• Venselaar H, te Beek TA, Kuipers RK, Hekkelman ML, Vriend G. Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces. BMC Bioinformatics. 2010;11:548.
   PubMed Web of Science ®Google Scholar
• Dominguez J, Yu JT, Tan YJ, Ng A, De Guzman MF, Natividad B, et al. Novel optineurin frameshift insertion in a family with frontotemporal dementia and Parkinsonism without amyotrophic lateral sclerosis. Front Neurol. 2021;12:645913.
   PubMed Web of Science ®Google Scholar
• Mehta PR, Jones AR, Opie-Martin S, Shatunov A, Iacoangeli A, Al Khleifat A, et al. Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias. J Neurol Neurosurg Psychiatry. 2019;90:268–71.
   PubMed Web of Science ®Google Scholar
• Stezin A, Chaithra SP, Holla VV, Kamble N, Yadav R, Pal PK. A novel OPTN variant causing PSP-CBS-like phenotype in familial amyotrophic lateral sclerosis. Parkinsonism Relat Disord. 2019;69:147–9.
   PubMed Web of Science ®Google Scholar
• Abate F, Dati G, Ginevrino M, Valente EM, Barone P, Picillo M. APP-related corticobasal syndrome: expanding the list of corticobasal degeneration look alikes. Mov Disord Clin Pract. 2020;7:849–51.
   PubMed Web of Science ®Google Scholar
• Weil R, Laplantine E, Curic S, Génin P. Role of optineurin in the mitochondrial dysfunction: potential implications in neurodegenerative diseases and cancer. Front Immunol. 2018;9:1243. Available at: https://www.frontiersin.org/articles/10<?sch-permit JATS-0034-007?>.3389/fimmu.2018.01243. Accessed November 24, 2022.
   PubMed Web of Science ®Google Scholar
• Pottier C, Bieniek KF, Finch N, van de Vorst M, Baker M, Perkersen R, et al. Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol. 2015;130:77–92.
   PubMed Web of Science ®Google Scholar
• Espay AJ, Litvan I. Parkinsonism and frontotemporal dementia: the clinical overlap. J Mol Neurosci. 2011;45:343–9.
   PubMed Web of Science ®Google Scholar
• Morimoto S, Hatsuta H, Motoyama R, Kokubo Y, Ishiura H, Tsuji S, et al. Optineurin pathology in the spinal cord of amyotrophic lateral sclerosis/parkinsonism-dementia complex patients in Kii Peninsula, Japan. Brain Pathol. 2018;28:422–6.
   PubMed Web of Science ®Google Scholar
• Kokubo Y, Morimoto S, Sasaki R, Hasegawa M, Ishiura H, Tsuji S, et al. An immigrant family with Kii amyotrophic lateral sclerosis/parkinsonism–dementia complex. Neurol Sci. 2022;43:1423–5.
   PubMed Web of Science ®Google Scholar
• Ayaki T, Ito H, Komure O, Kamada M, Nakamura M, Wate R, et al. Multiple proteinopathies in familial ALS cases with optineurin mutations. J Neuropathol Exp Neurol. 2018;77:128–38.
   PubMed Web of Science ®Google Scholar
• Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010;465:223–6.
   PubMed Web of Science ®Google Scholar
• Müller K, Brenner D, Weydt P, Meyer T, Grehl T, Petri S, et al. Comprehensive analysis of the mutation spectrum in 301 German ALS families. J Neurol Neurosurg Psychiatry. 2018;89:817–27.
   PubMed Web of Science ®Google Scholar
• Müller HP, Agosta F, Riva N, Spinelli EG, Comi G, Ludolph AC, et al. Fast progressive lower motor neuron disease is an ALS variant: a two-centre tract of interest-based MRI data analysis. Neuroimage Clin. 2018;17:145–52.
   PubMed Web of Science ®Google Scholar
• Sundaramoorthy V, Walker AK, Tan V, Fifita JA, Mccann EP, Williams KL, et al. Defects in optineurin- and myosin VI-mediated cellular trafficking in amyotrophic lateral sclerosis. Hum Mol Genet. 2015;24:3830–46.
   PubMed Web of Science ®Google Scholar
• Garg N, Park SB, Vucic S, Yiannikas C, Spies J, Howells J, et al. Differentiating lower motor neuron syndromes. J Neurol Neurosurg Psychiatry. 2017;88:474–83.
   PubMed Web of Science ®Google Scholar
• Yu B, Pamphlett R. Environmental insults: critical triggers for amyotrophic lateral sclerosis. Transl Neurodegener. 2017;6:15.
   PubMed Web of Science ®Google Scholar